Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited operates in Pharmaceuticals, part of the Healthcare sector.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-11.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,840 | ₹4.41 L cr | 38.0 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,322 | ₹2.47 L cr | 68.6 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,966 | ₹1.68 L cr | 83.5 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,119 | ₹1.12 L cr | 29.9 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,366 | ₹1.10 L cr | 35.0 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,969 | ₹1.06 L cr | 72.3 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,166 | ₹97,319 cr | 54.7 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,680 | ₹96,656 cr | 23.5 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,095 | ₹95,794 cr | 16.9 | 25.2% | 17.1% | — |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.